Features | Partner Sites | Information | LinkXpress
Sign In
TERARECON, INC.
SCHILLER AG
AMPRONIX

Proton Therapy for Prostate Cancer Patients Offers Long-Term Patient Survival with Optimal Quality of Life

By Medimaging International staff writers
Posted on 26 Feb 2014
Image: Patient preparing to undergo proton therapy (Photo courtesy of the University of Florida Proton Therapy Institute).
Image: Patient preparing to undergo proton therapy (Photo courtesy of the University of Florida Proton Therapy Institute).
Five years after having proton therapy for the treatment of early- and intermediate-risk prostate cancer, 99% of men are cancer-free and with excellent quality of life, according to new findings. Three-quarters of those patients with high-risk prostate cancer are also disease-free.

The University of Florida (UF) Proton Therapy Institute (Jacksonville, USA) study, published in the March 1, 2014, issue of the International Journal of Radiation Oncology Biology Physics, adds to the body of evidence pointing to an important role for proton therapy in the effective treatment of prostate cancer, according to Nancy P. Mendenhall, MD, lead author and medical director of the UF Proton Therapy Institute.

“These proton therapy results compare very favorably with IMRT [intensity-modulated radiation therapy] results, particularly for intermediate risk-disease, where disease control rates of 70%–85% are typical,” said Dr. Mendenhall, the associate chair of the UF College of Medicine department of radiation oncology. IMRT is a type of radiation that uses photons, or X-rays, to deliver radiation. Proton therapy utilizes protons, particles of an atom, to deliver radiation.

The study monitored 211 patients who participated in prospective Institutional Review-Board approved trials. In each track, patients were administered proton therapy over an eight-week period, a shorter interval than typical with IMRT, which may last nine to nine-and-a-half weeks. Researchers used standardized data-collecting techniques for both physician-reported and patient-reported outcomes.

The findings revealed cancer-free survival rates at five years for low-, intermediate-, and high-risk patients are 99%, 99%, and 76%, respectively, whereas overall survival rates are 93%, 88%, and 90%. Furthermore, the serious gastrointestinal and urologic complication rate is low, at 1.4% and 5.3%, respectively, for all patients. Patients also reported good outcomes in relation to both urologic and bowel functions.

Related Links:

University of Florida Proton Therapy Institute 



RADCAL
SuperSonic Imagine
RTI ELECTRONICS AB

Channels

MRI

view channel
Image: The quantitative character of the novel 3D technique on MR scans from a patient with primary liver cancer is demonstrated. Images A and B show the scan of the patient before being treated with chemoembolization. The new 3D technique helped quantify the volume and distribution of viable tumor tissue (shown in red and yellow colors). Images C and D demonstrate MR scans acquired after the treatment. The new 3D method helped the radiologists to quantify the vast central destruction of the tumor after the treatment (the dead tumor is represented by the blue color) (Photo courtesy of Johns Hopkins Medicine).

3D MRI Offers Improved Prediction of Survival After Chemotherapy for Liver Tumors

Researchers are using specialized three-dimensional (3D) magnetic resonance imaging (MRI) scanning technology to accurately measure living and dying liver tumor tissue in order to quickly show whether... Read more

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.